[go: up one dir, main page]

ATE334666T1 - Neue fettsäureanaloge zur behandlung der fettleber - Google Patents

Neue fettsäureanaloge zur behandlung der fettleber

Info

Publication number
ATE334666T1
ATE334666T1 AT02024388T AT02024388T ATE334666T1 AT E334666 T1 ATE334666 T1 AT E334666T1 AT 02024388 T AT02024388 T AT 02024388T AT 02024388 T AT02024388 T AT 02024388T AT E334666 T1 ATE334666 T1 AT E334666T1
Authority
AT
Austria
Prior art keywords
sub
treatment
acid analogues
fatty acid
new
Prior art date
Application number
AT02024388T
Other languages
English (en)
Inventor
Rolf Berge
Original Assignee
Thia Medica As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica As filed Critical Thia Medica As
Application granted granted Critical
Publication of ATE334666T1 publication Critical patent/ATE334666T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT02024388T 1998-05-08 1999-04-23 Neue fettsäureanaloge zur behandlung der fettleber ATE334666T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS

Publications (1)

Publication Number Publication Date
ATE334666T1 true ATE334666T1 (de) 2006-08-15

Family

ID=19907879

Family Applications (5)

Application Number Title Priority Date Filing Date
AT02024388T ATE334666T1 (de) 1998-05-08 1999-04-23 Neue fettsäureanaloge zur behandlung der fettleber
AT99933292T ATE247464T1 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung der fettleibigkeit
AT02024616T ATE336239T1 (de) 1998-05-08 1999-04-23 Neue fettsäureanaloge zur behandlung des bluthochdrucks
AT99933293T ATE245416T1 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung von diabetes
AT99940723T ATE306916T1 (de) 1998-05-08 1999-05-07 Neue fettanaloge zur behandlung von sekundärer restenose

Family Applications After (4)

Application Number Title Priority Date Filing Date
AT99933292T ATE247464T1 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung der fettleibigkeit
AT02024616T ATE336239T1 (de) 1998-05-08 1999-04-23 Neue fettsäureanaloge zur behandlung des bluthochdrucks
AT99933293T ATE245416T1 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung von diabetes
AT99940723T ATE306916T1 (de) 1998-05-08 1999-05-07 Neue fettanaloge zur behandlung von sekundärer restenose

Country Status (17)

Country Link
US (4) US6365628B1 (de)
EP (5) EP1285652B1 (de)
JP (3) JP2002514595A (de)
KR (3) KR100701503B1 (de)
CN (3) CN1245157C (de)
AT (5) ATE334666T1 (de)
AU (4) AU7240398A (de)
BR (2) BR9910296A (de)
CA (3) CA2331395C (de)
DE (5) DE69932864D1 (de)
DK (3) DK1075259T3 (de)
ES (3) ES2207253T3 (de)
NO (3) NO20005463L (de)
NZ (3) NZ508045A (de)
PT (2) PT1075259E (de)
RU (3) RU2219920C2 (de)
WO (4) WO1999058120A1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
CA2388754C (en) * 1999-10-13 2010-07-13 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
NO328803B1 (no) * 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
NO20004844L (no) * 2000-09-27 2002-05-10 Thia Medica As Fettsyre analoger for behandling av proliferative hudsykdommer
NO20006008L (no) 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
DK1547614T3 (da) * 2002-05-28 2011-04-04 Ajinomoto Kk Medicinsk sammensætning til inhibering af ekspressionen af ATP-citrat-lyase og anvendelse deraf
CN100351259C (zh) * 2002-06-20 2007-11-28 Icvec有限公司 含硫的磷脂衍生物
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
PL377087A1 (pl) 2002-09-06 2006-01-23 Janssen Pharmaceutica, N.V. Związki heterocykliczne
MXPA05003346A (es) * 2002-09-27 2005-11-23 Martek Biosciences Corp Control glicemico mejorado para prediabetes y/o diabetes tipo ii utilizando acido docosahexaenoico.
CA2501318A1 (en) * 2002-10-10 2004-04-22 Yeda Research And Development Co. Ltd Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
FR2850650B1 (fr) * 2003-01-31 2005-03-25 Genfit S A Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures
FR2850869B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures
EP1594439A2 (de) * 2003-02-13 2005-11-16 Albert Einstein College Of Medicine Of Yeshiva University Regulierung der nahrungsaufnahme und glukoseproduktion durch modulation der spiegel von langkettigem fettsäureacyl-coa im hypothalamus
RU2356247C2 (ru) * 2003-03-18 2009-05-27 Новартис Аг Комбинации и композиции, содержащие жирные кислоты и аминокислоты, их применение для предупреждения, замедления прогрессирования или лечения диабета и связанных с диабетом заболеваний и состояний, способ снижения веса тела млекопитающего, набор
WO2005073164A1 (en) * 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20070259435A1 (en) * 2004-05-28 2007-11-08 Janssen Pharmaceutica N.V. Intravenous Drug Administration and Blood Sampling Model in the Awake Rat
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
NO324534B1 (no) * 2004-07-19 2007-11-19 Thia Medica As Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav
MX2007000816A (es) * 2004-07-19 2007-06-05 Thia Medica As Composicion que comprende material de proteina y compuestos que comprenden entidades de acido graso no oxidable.
RU2394598C2 (ru) * 2004-07-19 2010-07-20 Тиа Медика Ас Композиция, содержащая белковый материал и соединения, содержащие неокисляющиеся структурные элементы жирных кислот
RU2272628C1 (ru) * 2004-07-19 2006-03-27 Илья Николаевич Медведев Способ быстрой оптимизации функций кровяных пластинок при метаболическом синдроме
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
WO2006083439A2 (en) * 2004-12-28 2006-08-10 The Research Foundation Of State University Of New York At Buffalo Method for lowering serum homocysteine
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
RU2441061C2 (ru) * 2005-05-04 2012-01-27 Пронова Биофарма Норге Эс. Производные докозагексаеновой кислоты и их применение в качестве лекарственных средств
JP5337479B2 (ja) 2005-05-04 2013-11-06 プロノヴァ・バイオファーマ・ノルゲ・アーエス 新規化合物
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
ES2618500T3 (es) 2006-10-20 2017-06-21 Neurendo Pharma, Llc Método para restaurar el efecto incretina
EP2094640A4 (de) * 2006-11-01 2015-05-20 Pronova Biopharma Norge As Alpha-substituierte omega-3-lipide, bei denen es sich um aktivatoren oder modulatoren des peroxisomproliferatoraktivierten rezeptors (ppar) handelt
US20100240616A1 (en) * 2006-11-01 2010-09-23 Anne Kristin Holmeide Novel lipid compounds
WO2008106091A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Use of long-chain alcohol derivatives for the treatment of alopecia areata
US7964751B2 (en) * 2007-02-26 2011-06-21 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec-9-(Z) enyl ester, their salts and their uses
CA2702577A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
WO2009056983A1 (en) * 2007-10-31 2009-05-07 Pronova Biopharma Norge As New dha derivatives and their use as medicaments
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
RU2502727C2 (ru) * 2008-04-29 2013-12-27 Ф.Хоффманн-Ля Рош Аг 4-триметиламмониобутираты в качестве ингибиторов срт2
EP2147910A1 (de) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Neue Lipid-Verbindungen
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
US8650937B2 (en) 2008-09-19 2014-02-18 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
EA021177B1 (ru) 2009-05-08 2015-04-30 Пронова Биофарма Норге Ас Полиненасыщенные жирные кислоты для лечения заболеваний, связанных с сердечно-сосудистыми, метаболическими и воспалительными заболеваниями
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US9211377B2 (en) 2009-07-30 2015-12-15 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
CN103237546B (zh) 2010-07-28 2016-06-08 生命科技公司 抗病毒的含有叠氮化物的化合物
ES2618604T3 (es) 2010-11-05 2017-06-21 Pronova Biopharma Norge As Métodos de tratamiento usando compuestos lipídicos
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
KR102213143B1 (ko) 2013-02-28 2021-02-08 바스프 에이에스 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법
CA2904898C (en) 2013-03-11 2019-10-15 Jan Remmereit Lipid compositions containing bioactive fatty acids
HK1220606A1 (zh) 2013-03-11 2017-05-12 Nobesita As 包含非可氧化脂肪酸的天然脂类
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (ru) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Способ лечения острого гепатоза у кошек
ES2787223T3 (es) 2014-11-07 2020-10-15 Univ Minnesota Sales y composiciones útiles para tratar enfermedades
KR102644400B1 (ko) 2015-04-28 2024-03-06 바스프 에이에스 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
EP3661600A4 (de) * 2017-10-23 2021-08-11 Epitracker, Inc. Fettsäure-analoga und ihre verwendung zur behandlung von erkrankungen im zusammenhang mit dem stoffwechselsyndrom
US11925614B2 (en) 2017-12-06 2024-03-12 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
JP2021525249A (ja) 2018-05-23 2021-09-24 エピトラッカー インコーポレイテッドＥｐｉｔｒａｃｋｅｒ， Ｉｎｃ． 加齢及び長期性の質に関連する状態の診断及び治療のための組成物及び方法
WO2020146263A1 (en) 2019-01-09 2020-07-16 Epitracker, Inc. Compositions and methods for diagnosis and treatment of neurodegenerative diseases
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
WO2023080939A1 (en) 2021-11-03 2023-05-11 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity
KR20250043868A (ko) 2023-09-22 2025-03-31 건국대학교 산학협력단 옥시리핀을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (ja) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd 脳卒中予防剤
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
AU6277396A (en) * 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
EP0843972B1 (de) * 1996-11-20 2002-07-31 N.V. Nutricia Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselssyndroms
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS

Also Published As

Publication number Publication date
CA2331393A1 (en) 1999-11-18
US6417232B1 (en) 2002-07-09
NO20005462L (no) 2001-01-08
CN1245157C (zh) 2006-03-15
US6441036B1 (en) 2002-08-27
CA2331393C (en) 2009-08-11
US6365628B1 (en) 2002-04-02
DK1075260T3 (da) 2006-02-06
WO1999058122A1 (en) 1999-11-18
JP2002514596A (ja) 2002-05-21
CN1244323C (zh) 2006-03-08
US7026356B2 (en) 2006-04-11
EP1284139B1 (de) 2006-08-02
HK1034912A1 (en) 2001-11-09
CA2331395C (en) 2008-10-14
ES2204142T3 (es) 2004-04-16
DE69909775D1 (de) 2003-08-28
JP5057003B2 (ja) 2012-10-24
DE69910559T2 (de) 2004-06-17
NO333143B1 (no) 2013-03-18
ATE247464T1 (de) 2003-09-15
BR9910297A (pt) 2002-01-02
NZ508046A (en) 2003-08-29
WO1999058120A1 (en) 1999-11-18
AU762792B2 (en) 2003-07-03
PT1075258E (pt) 2004-01-30
KR20010043314A (ko) 2001-05-25
ATE245416T1 (de) 2003-08-15
HK1034911A1 (en) 2001-11-09
DK1075258T3 (da) 2003-12-01
AU761355B2 (en) 2003-06-05
DE69910559D1 (de) 2003-09-25
EP1075259B1 (de) 2003-07-23
NO20005463D0 (no) 2000-10-30
WO1999058123A3 (en) 2000-03-09
ES2251218T3 (es) 2006-04-16
NO20005463L (no) 2001-01-08
AU4936699A (en) 1999-11-29
DE69932645D1 (de) 2006-09-14
NO20005461D0 (no) 2000-10-30
US20020198259A1 (en) 2002-12-26
ATE306916T1 (de) 2005-11-15
KR100822077B1 (ko) 2008-04-14
NZ508045A (en) 2003-08-29
RU2221558C2 (ru) 2004-01-20
KR100701503B1 (ko) 2007-04-02
NO20005461L (no) 2001-01-08
EP1075260B1 (de) 2005-10-19
ATE336239T1 (de) 2006-09-15
BR9910296A (pt) 2002-01-15
EP1075259A1 (de) 2001-02-14
EP1285652A1 (de) 2003-02-26
EP1075258B1 (de) 2003-08-20
EP1284139A1 (de) 2003-02-19
HK1034909A1 (en) 2001-11-09
AU762790B2 (en) 2003-07-03
DE69927805D1 (de) 2006-03-02
EP1285652B1 (de) 2006-08-16
EP1075260A2 (de) 2001-02-14
PT1075259E (pt) 2003-12-31
KR20010043316A (ko) 2001-05-25
DE69927805T2 (de) 2006-07-06
AU7240398A (en) 1999-11-29
JP4465672B2 (ja) 2010-05-19
RU2223095C2 (ru) 2004-02-10
CN1302204A (zh) 2001-07-04
WO1999058123A2 (en) 1999-11-18
EP1075258A1 (de) 2001-02-14
CA2331408A1 (en) 1999-11-18
KR100701502B1 (ko) 2007-04-02
KR20010043315A (ko) 2001-05-25
JP2002514594A (ja) 2002-05-21
CA2331408C (en) 2008-10-21
JP2002514595A (ja) 2002-05-21
DE69932864D1 (de) 2006-09-28
AU5451799A (en) 1999-11-29
CN1300211A (zh) 2001-06-20
NZ508047A (en) 2003-05-30
CA2331395A1 (en) 1999-11-18
ES2207253T3 (es) 2004-05-16
DE69909775T2 (de) 2004-06-03
WO1999058121A1 (en) 1999-11-18
CN1300212A (zh) 2001-06-20
DK1075259T3 (da) 2003-11-03
RU2219920C2 (ru) 2003-12-27
CN1223343C (zh) 2005-10-19
AU4936799A (en) 1999-11-29
NO20005462D0 (no) 2000-10-30

Similar Documents

Publication Publication Date Title
DE69932645D1 (de) Neue Fettsäureanaloge zur Behandlung der Fettleber
DE69512797D1 (en) Prostaglandin-synthase hemmer
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
IL129068A0 (en) Sulfinic acid derivatives and their preparation and use
ATE297731T1 (de) Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol
DK1144365T3 (da) Inhibitorer af alfa4beta1-medieret celleadhæsion
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
BR0212899A (pt) Compostos orgânicos
DE69928820D1 (de) Akt zusammensetzungen zur steigerung des überlebens von kardiomyozyten
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
ATE536886T1 (de) Stabilisierte feste zusammensetzungen von modifizierter faktor vii
DK0865271T4 (da) Anvendelse af 2-ethylhexyl alfa-cyano-beta, beta-diphenylacrylat med henblik på at forbedre stabiliteten over for lys af p-methylbenzyliden-kamfer
ATE299851T1 (de) Verfahren zur herstellung von zwischenprodukten
DE60204014D1 (de) Chlormethylierung von thiophene
DE59803066D1 (de) Substituierte benzyloxyimino-verbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties